Phathom Pharmaceuticals, Inc.
PHAT Nasdaq
SEC CIK 1783183
Follow Phathom Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$84.7M
+71.1% vs same quarter last year
Net income
−$13.9M
+53.6% vs same quarter last year
EPS, diluted
−$0.16
+61% vs same quarter last year
Operating cash flow
$1.8M
+113% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $175.1M | −$221.3K |
| FY24 | $55.3M | −$334.3K |
| FY23 | $682K | −$201.6K |
| FY22 | $0 | −$197.7M |
| FY21 | - | −$143.9M |
| FY20 | - | −$129.1M |
| FY19 | - | −$255.1M |
| FY18 | - | −$1.3M |
| FY17 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 87.1% | −91.4% | −0.1% |
| FY24 | 85.6% | −502.2% | −0.6% |
| FY23 | 75.5% | −24532.6% | −29.6% |
| FY22 | - | - | - |
| FY21 | - | - | - |
| FY20 | - | - | - |
| FY19 | - | - | - |
| FY18 | - | - | - |
| FY17 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$167M |
| FY24 | −$266.9M |
| FY23 | −$139.2M |
| FY22 | −$147.6M |
| FY21 | −$148.8M |
| FY20 | −$70.7M |
| FY19 | −$36.6M |
| FY18 | - |
| FY17 | - |
- Phathom Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Phathom Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −0.1% | −30.6% |
| FY24 | −0.6% | −47% |
| FY23 | −29.6% | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.8% |
| FY20 | - | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |